Every Problem Has a Workable Solution
We are a uniquely qualified business research, analytics and consulting firm with a 100% focus on the biopharmaceutical, medical devices, healthcare, and diagnostics domains.
We are a uniquely qualified business research, analytics and consulting firm with a 100% focus on the biopharmaceutical, medical devices, healthcare, and diagnostics domains.
Therapy Area Assessments
Epidemiology Analysis
Revenue Forecasts
KOL Ranking, Profiling and Influence Mapping
Lifecycle Management Projects
Our in-licensing opportunity assessment helps healthcare and pharmaceutical companies evaluate potential products or technologies developed externally
We conduct rigorous analyses of scientific validity and development feasibility for potential pipeline assets, ensuring alignment with clinical, regulatory, and technical benchmarks. Simultaneously, we evaluate the asset’s commercial viability and market readiness, assessing its differentiation, competitive positioning, and uptake potential across target geographies.
We blend market intelligence with predictive modeling to estimate future financial performance of drugs or portfolios.
We design and develop forecast models to estimate how much revenue a drug or therapeutic product will generate over a given time horizon — from pre-launch planning to peak years and eventual decline. Our custom forecast model helps drive decisions across R&D investment, licensing, market access, and portfolio strategy.
We assess how uncertainty in key inputs affects the reliability and strategic value of economic or valuation models—particularly in the context of licensing, pricing, and reimbursement decisions across the life sciences landscape.
Through tailored sensitivity and scenario analyses, we test the robustness of asset valuations and cost-effectiveness frameworks, spotlighting critical assumptions that materially influence decision outcomes
We offer targeted consulting solutions across the full drug development and commercialization lifecycle, designed to resolve high-stakes business problems with precision and therapeutic insight.
We provide epidemiology-driven consulting that anchors strategic decisions in real-world disease burden, patient segmentation, and treatment dynamics. Our capabilities span the full spectrum—from foundational epidemiologic assessments to market-impact modeling—integrated seamlessly with clinical, commercial, and access strategy.
We don’t just report epidemiologic statistics—we turn them into actionable intelligence that supports confident choices across R&D, licensing, and market access planning.
We deliver precision-driven KOL ranking mapping that empowers pharma, medtech, and diagnostics companies to engage the right thought leaders—at the right time, with the right message. Our approach blends scientific expertise, digital listening, and network analytics to create dynamic profiles and strategic engagement plans.
Our influence maps aren’t just visual—they’re strategic blueprints for market activation, MSL targeting, and stakeholder alignment across the drug lifecycle.
Disease Insights Book is the backbone of strategic decision-making in healthcare innovation. It involves deep dives into specific medical domains to understand disease burden, treatment landscapes, pipeline dynamics, and unmet needs.
We create custom therapy reports with focused analysis of a medical specialty (e.g., oncology, antibody–drug conjugates, rare diseases) to inform clinical development, market strategy, and investment decisions.
Our Systematic Analysis in Health Economics is a structured, evidence-based approach to evaluating the costs, outcomes, and value of healthcare interventions, policies, or technologies. It’s foundational to Health Technology Assessment (HTA), reimbursement decisions, and strategic resource allocation.
We use our proprietary systematic analysis framework for a specific therapy area or asset evaluation and structure it around epidemiology, cost inputs, and strategic decision points.